Taysha Gene Therapies, Inc. (TSHA)
| Market Cap | 2.09B +213.2% |
| Revenue (ttm) | 7.47M +3.4% |
| Net Income | -129.88M |
| EPS | -0.38 |
| Shares Out | 319.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,325,112 |
| Open | 6.70 |
| Previous Close | 6.65 |
| Day's Range | 6.40 - 6.81 |
| 52-Week Range | 2.33 - 7.30 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+99.08%) |
| Earnings Date | Aug 11, 2026 |
About TSHA
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-... [Read more]
Financial Performance
In 2025, Taysha Gene Therapies's revenue was $9.77 million, an increase of 17.28% compared to the previous year's $8.33 million. Losses were -$109.00 million, 22.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TSHA stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 99.08% from the latest price.
News
Taysha Gene Therapies price target raised to $15 from $12 at Baird
Baird raised the firm’s price target on Taysha Gene Therapies (TSHA) to $15 from $12 and keeps an Outperform rating on the shares. The firm updated its model as they…
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity
Taysha Gene Therapies management to meet with Piper Sandler
Meeting to be held in Minneapolis on June 30 hosted by Piper Sandler.
Taysha Gene Therapies 32.5M share Spot Secondary priced at $6.00
The deal priced below last closing price of $6.94. Baird is acting as sole book running manager for the offering.
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b...
Taysha Gene Therapies announces $200M common stock offering
Taysha Gene Therapies (TSHA) announced that it has commenced an underwritten public offering of $200M shares of its common stock and, in lieu of common stock to certain investors that…
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b...
Taysha Gene Therapies price target raised to $14 from $10 at BMO Capital
BMO Capital analyst Keith Tapper raised the firm’s price target on Taysha Gene Therapies (TSHA) to $14 from $10 and keeps an Outperform rating on the shares after the company…
Taysha Gene Therapies price target raised to $14 from $10 at BMO Capital
BMO Capital analyst Keith Tapper raised the firm’s price target on Taysha Gene Therapies (TSHA) to $14 from $10 and keeps an Outperform rating on the shares after the company…
Taysha Gene Therapies price target raised to $10 from $9 at BofA
BofA raised the firm’s price target on Taysha Gene Therapies (TSHA) to $10 from $9 and keeps a Buy rating on the shares after the company reported an update for…
Taysha Gene Therapies price target raised to $11 from $8 at Citizens
Citizens raised the firm’s price target on Taysha Gene Therapies (TSHA) to $11 from $8 and keeps an Outperform rating on the shares. Updated REVEAL Part A data from Taysha…
Taysha Gene Therapies Transcript: Study result
Dosing is complete in the pivotal REVEAL trial for TSHA-102 in Rett syndrome, with 100% of patients achieving developmental milestones and significant, durable gains. TSHA-102 was well-tolerated, and the FDA supports a potential BLA submission based on six-month interim data. Top-line data and FDA feedback are expected in H1 2027.
Taysha Gene Therapies Press release: Study result
Taysha Gene Therapies issued a press release on June 22, 2026, disclosing material business information to investors.
Taysha Gene Therapies Slides: Study result
Taysha Gene Therapies has posted slides in relation to its latest quarterly earnings report, which was published on June 22, 2026.
Taysha Gene Therapies completes dosing in REVEAL pivotal trial
Taysha Gene Therapies (TSHA) announced the completion of dosing in the REVEAL pivotal trial and reported longer-term clinical data from Part A of the REVEAL Phase 1/2 trials evaluating TSHA-102…
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
DALLAS, June 22, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b...
Taysha Gene Therapies Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation votes. All proposals passed, including annual advisory votes on compensation. No shareholder questions were submitted.
Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c)
“We continued to execute our clinical development strategy for TSHA-102 and recently reaffirmed alignment with the FDA on our pathway to a BLA filing, including trial design, endpoints and the…
Taysha Gene Therapies Earnings Call Transcript: Q1 2026
TSHA-102 clinical and regulatory progress continued, with pivotal trial dosing on track for Q2 2026 and strong FDA alignment on BLA submission scenarios. Financials reflect increased R&D investment, and market research shows high demand for gene therapy with preference for intrathecal delivery.
Taysha Gene Therapies Earnings release: Q1 2026
Taysha Gene Therapies released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Taysha Gene Therapies Quarterly report: Q1 2026
Taysha Gene Therapies has published its Q1 2026 quarterly earnings report on May 6, 2026.
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-ba...
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-...
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TS...